Filter by cancer type, molecular target, phase, and recruitment status.
Loading filters…
Primary analysis
Gastric / esophageal
NEJM May 2026: PFS 12.4 vs 8.1 mo (zanidatamab±tislelizumab). Separate from DESTINY-Gastric04 / SPOTLIGHT.
Registry checked: 2026-10-29
Interim analysis
Pancreas · Multiple / solid tumors
Phase I; NEJM 2026. ~24% ORR in PDAC 600 mg cohort — early signal; not standard care.
Registry checked: 2026-10-29
2 / 51 studies · “Newly reported results” only
Primary analysis
Gastric / esophageal
NEJM May 2026: PFS 12.4 vs 8.1 mo (zanidatamab±tislelizumab). Separate from DESTINY-Gastric04 / SPOTLIGHT.
Registry checked: 2026-10-29
Interim analysis
Pancreas · Multiple / solid tumors
Phase I; NEJM 2026. ~24% ORR in PDAC 600 mg cohort — early signal; not standard care.
Registry checked: 2026-10-29